1. Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
- Author
-
Joanne M O'Rourke, Nekisa Zakeri, Yuk Ting Ma, Tu Vinh Luong, Sam Khan, Chinenye Iwuji, Essam Hashem, Dominic Yu, Alexa Childs, Richard A Hubner, Tim Meyer, Joanna L Connor, Daniel H. Palmer, Kimberley Hockenhull, Chiara Braconi, Suzanne Darby, Daniel Swinson, Paul Ross, and Tom Roques
- Subjects
Adult ,Male ,Sorafenib ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,Biopsy ,Chronic liver disease ,Article ,Cholangiocarcinoma ,Young Adult ,Liver disease ,Predictive Value of Tests ,medicine ,Humans ,Prospective Studies ,Case report form ,Aged ,Aged, 80 and over ,Performance status ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,digestive system diseases ,United Kingdom ,Oncology ,Cohort ,Radiology ,Tomography, X-Ray Computed ,business ,medicine.drug - Abstract
Background Advanced hepatocellular carcinoma (HCC) is commonly diagnosed using non-invasive radiological criteria (NIRC) defined by the European Association for the Study of the Liver or the American Association for the Study of Liver Diseases. In 2017, The National Institute for Clinical Excellence mandated histological confirmation of disease to authorise the use of sorafenib in the UK. Methods This was a prospective multicentre audit in which patients suitable for sorafenib were identified at multidisciplinary meetings. The primary analysis cohort (PAC) was defined by the presence of Child-Pugh class A liver disease and performance status 0โ2. Clinical, radiological and histological data were reported locally and collected on a standardised case report form. Results Eleven centres reported 418 cases, of which 361 comprised the PAC. Overall, 76% had chronic liver disease and 66% were cirrhotic. The diagnostic imaging was computed tomography in 71%, magnetic resonance imaging in 27% and 2% had both. Pre-existing histology was available in 45 patients and 270 underwent a new biopsy, which confirmed HCC in 93.4%. Alternative histological diagnoses included cholangiocarcinoma (CC) and combined HCC-CC. In cirrhotic patients, NIRC criteria had a sensitivity of 65.4% and a positive predictive value of 91.4% to detect HCC. Two patients (0.7%) experienced mild post-biopsy bleeding. Conclusion The diagnostic biopsy is safe and feasible for most patients eligible for systemic therapy
- Published
- 2021
- Full Text
- View/download PDF